ライフサイエンスコーパス: vertigo

1 ort, chronic subjective dizziness and visual vertigo).

2 treatment-related pulmonary embolism and one vertigo.

3 the brainstem and cerebellum that can cause vertigo.

4 reatment options exist for the management of vertigo.

5 through which gentamicin leads to control of vertigo.

6 ally required in order to achieve control of vertigo.

7 pathophysiological model of migraine-related vertigo.

8 symptoms in patients with both migraine and vertigo.

9 dge of the pathogenesis of both migraine and vertigo.

10 ith mild tinnitus but is not associated with vertigo.

11 ase, 5 of 9 had improvement or resolution of vertigo.

12 ents with a history of positionally provoked vertigo.

13 recurrent attacks of vertigo, and positional vertigo.

14 ntiation of peripheral and central causes of vertigo.

15 ause or exacerbate symptoms in patients with vertigo.

16 g younger male patients without a history of vertigo.

17 gressive bilateral hearing loss and/or acute vertigo.

18 e with improvement in any outcomes for acute vertigo.

19 esented with recurrent falls precipitated by vertigo.

20 mine use may not benefit patients with acute vertigo.

21 ops and sensorineural hearing, nystagmus, or vertigo.

22 being sought for a study about patients with vertigo.

23 egarding diagnostic methods for cervicogenic vertigo.

24 e over the last year concerning cervicogenic vertigo.

25 positioning for benign paroxysmal positional vertigo.

26 symptoms include diplopia, oscillopsia, and vertigo.

27 eral and can be associated with tinnitus and vertigo.

28 mab: one case of urosepsis and an episode of vertigo.

29 improve diagnosis and treatment of recurrent vertigo.

30 ne is among the commonest causes of episodic vertigo.

31 hearing loss (9.2% vs. 6.8%, p < 0.001), and vertigo (14.4% vs. 11.1%, p < 0.001).

32 ssifications of benign paroxysmal positional vertigo (23 [37.1%]), triggered undifferentiated dizzine

33 ong TH patients were 60.63% headache, 17.02% vertigo, 4.25% seizures, 3.19% tremor, 3.19% syncope, 7.

34 tan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds r

35 s included hearing loss (13), tinnitus (12), vertigo (8), and facial paresis (1).

36 Of 16 patients with vertigo, 8 (50%) were improved, 7 (47%) unchanged, and 1

37 Physicians find acute vertigo a diagnostic challenge.

38 gn paroxysmal torticollis, benign paroxysmal vertigo, abdominal migraine, and cyclic vomiting syndrom

39 lantar erythrodysesthesia, nausea, vomiting, vertigo, abdominal pain, diarrhea, and thrombocytopenia.

40 use of spontaneous (non-positional) episodic vertigo, affecting up to 1% of the population.

41 hed criteria for the diagnosis of migrainous vertigo allows the development of a standardized, struct

42 Individuals with vestibular vertigo also had a threefold increased odds of depressio

43 tinnitus, hearing loss, sudden deafness, and vertigo among patients with PM/DM versus comparison pati

44 rved an 8.4% 1-year prevalence of vestibular vertigo among US adults.

45 story of intermittent emesis, dizziness, and vertigo and a 1-day history of wobbly gait and bilateral

46 story of intermittent emesis, dizziness, and vertigo and a 1-day history of wobbly gait and bilateral

47 mic burden of recurrent vestibular causes of vertigo and areas contributing to the cost is needed.

48 dic ataxia type 2 is a prototypical episodic vertigo and ataxia syndrome that is caused by mutations

49 Two sons have episodes of vertigo and ataxia that are not responsive to acetazolam

50 peutic challenges associated with dizziness, vertigo and balance disorders.

51 his review focuses on prospective studies of vertigo and balance therapy in the past 3 years, includi

52 ied the pathophysiology of benign positional vertigo and documented the efficacy of particle repositi

53 ted to the hospital with severe non-systemic vertigo and dysarthria, which had lasted for a couple of

54 overlap between vestibular symptoms, such as vertigo and head-movement intolerance, and migraine symp

55 r, is characterized by debilitating episodic vertigo and hearing fluctuations, progressing to permane

56 dissociate vestibular impairments that cause vertigo and imbalance in patients.

57 acetyl-D,L-leucine is approved in France for vertigo and its L-enantiomer is being developed as a dru

58 lapping and interrelated problems of emesis, vertigo and migraine which promises an early solution to

59 n for a correlation between benign recurrent vertigo and migraine, and acceptance for vertigo as a ma

60 s, postoperative nausea and vomiting (PONV), vertigo and morning sickness and observing new associati

61 The effects of head pitch on vertigo and previously reported nystagmus are consistent

62 ng different familial syndromes of recurrent vertigo and strong association with migraine suggest sha

63 tery can cause neurological symptoms such as vertigo and syncope.

64 When present, vertigo and tinnitus were assessed by frequency and seve

65 orineural hearing loss, often accompanied by vertigo and tinnitus.

66 the percentage of attacks with reductions in vertigo and unsteadiness/dizziness from moderate or seve

67 story of dysarthria, progressively worsening vertigo, and difficulty walking.

68 rineural hearing loss, tinnitus and episodic vertigo, and familial MD is observed in 5-15% of sporadi

69 ular systems, such as hoarseness, dizziness, vertigo, and fever symptoms.

70 nking, disorientation, balance disturbances, vertigo, and impotence), and 3 ("arthro-myo-neuropathy,"

71 aracterized by spells of ataxia, dysarthria, vertigo, and migraines, associated with mutations in the

72 ed spontaneous vertigo, recurrent attacks of vertigo, and positional vertigo.

73 e severity of hearing loss, age, presence of vertigo, and shape of the audiogram.

74 ts of psychogenic dizziness, phobic postural vertigo, and space-motion phobia.

75 ndings have not made the assessment of acute vertigo any easier for the nonspecialist.

76 ty loci for migraine and migraine-associated vertigo are underway.

77 ent vertigo and migraine, and acceptance for vertigo as a manifestation of migraine; efforts to ident

78 utoimmune disorders include hearing loss and vertigo as part of their constellation of symptoms.

79 neurological condition that causes episodic vertigo associated with other features of migraine.

80 re concerning cervicogenic vertigo including vertigo associated with rotational vertebral artery synd

81 cterized by recurrent attacks of spontaneous vertigo associated with sensorineural hearing loss (SNHL

82 at 2 hours, and improvement or resolution of vertigo at 1 week or 1 month.

83 She had no nystagmus or vertigo at pneumatic otoscopy.

84 an with a history of seminoma presented with vertigo, ataxia, and diplopia.

85 symptoms (eg, isolated diplopia, dysarthria, vertigo, ataxia, sensory loss, and bilateral visual dist

86 Meniere's disease is characterised by severe vertigo attacks and hearing loss.

87 The mean (SD) time until no positional vertigo attacks could be induced in the SM-plus group wa

88 The vertigo attacks have not occurred for the last 18 months

89 is (ie, all 60 patients), the mean number of vertigo attacks in the final 6 months compared with the

90 ry of acute otitis media, otorrhea, otalgia, vertigo, autophony, or tinnitus since her adoption.

91 Accurate diagnosis of acute vertigo (AV) in emergency settings is crucial due to var

92 h static magnetic fields are known to induce vertigo, believed to be via stimulation of the vestibula

93 The most common cause of vertigo, benign paroxysmal positional vertigo, can be cu

94 yclical vomiting syndrome, benign paroxysmal vertigo, benign paroxysmal torticollis and infantile col

95 ecurrent vertigo (mainly migraine-associated vertigo), bilateral vestibulopathy, and Meniere's diseas

96 pain after a post-treatment liver biopsy and vertigo), both unrelated to study drugs.

97 responsible for benign paroxysmal positional vertigo (BPPV) in humans.

98 Benign Paroxysmal Positional Vertigo (BPPV) is one of the most prevalent peripheral v

99 loped bilateral benign paroxysmal positional vertigo (BPPV) of the posterior canals, deafness, and ab

100 on condition of benign paroxysmal positional vertigo (BPPV).

101 ypofunction and benign paroxysmal positional vertigo (BPPV).

102 ated balance disorders and Benign Positional Vertigo (BPV).

103 Benign recurrent vertigo (BRV) is a common disorder affecting up to 2% of

104 e is commonly used to treat acute peripheral vertigo but may cause sedation.

105 (VM) is the most common cause of spontaneous vertigo but remains poorly understood.

106 nt for refractory Meniere's disease, reduces vertigo, but damages vestibular function and can worsen

107 use of vertigo, benign paroxysmal positional vertigo, can be cured with a simple positional manoeuvre

108 positional vertigo, the most common cause of vertigo, can now be cured with a simple bedside maneuver

109 report we describe a patient complaining of vertigo caused by spontaneous rupture of dermoid cyst, p

110 evaluated the association between vestibular vertigo, cognitive impairment (memory loss, difficulty c

111 evaluated the association between vestibular vertigo, cognitive impairment and psychiatric conditions

112 ical trial of patients with acute peripheral vertigo, combination therapy provided better symptom rel

113 he corticosteroid methylprednisolone reduces vertigo compared with gentamicin.

114 estibular neurectomy has a very high rate of vertigo control and is available for patients with good

115 t was the number of days until no positional vertigo could be induced on 3 consecutive mornings.

116 bloating and recurrent falls precipitated by vertigo, dehydration, acute kidney injury and electrolyt

117 Patients whose vertigo did not improve after injection (ie, non-respond

118 Patient bioeffects such as vertigo, dizziness, false feelings of motion, nausea, ny

119 rally well tolerated, but asthenia, fatigue, vertigo, dizziness, sense of imbalance, and loss of conc

120 descending order of frequency): hemiparesis, vertigo/dizziness, diplopia, dysarthria, nystagmus, naus

121 ing that any 'perceptual noise' added by the vertigo does not disrupt the cognitive decision-making p

122 stibular symptoms and patients with episodic vertigo due to a peripheral inner-ear disorder.

123 Vertigo due to cerebrovascular disease can be of periphe

124 nt isolated brainstem symptoms (eg, isolated vertigo, dysarthria, diplopia) are not consistently clas

125 common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed mor

126 is manifestations (hearing loss, four; acute vertigo, eight; both, three).

127 tive treatment that would reduce or stop the vertigo episodes has not been identified.

128 cument whether they could provoke positional vertigo every morning.

129 ) on qualitative and quantitative aspects of vertigo experienced in the dark by healthy humans when e

130 ess and dizziness (VUD, also known as visual vertigo), fear of falling (FoF), and chronic subjective

131 D) is a chronic disease that causes episodic vertigo, fluctuating hearing loss, and aural fullness, i

132 ith Meniere's disease, a disease of episodic vertigo, fluctuating hearing loss, tinnitus, and aural f

133 e is characterized by spontaneous attacks of vertigo, fluctuating sensorineural hearing loss, aural f

134 Quantitative analysis of vertigo focused on the induced perception of horizontal-

135 The primary outcome was vertigo frequency over the final 6 months (18-24 months

136 y in the past 3 years, including advances in vertigo-habituation exercises for adults, pediatric inte

137 ed for the efficacy of a minimal, home-based vertigo-habituation program for adults with peripheral v

138 justed analyses, individuals with vestibular vertigo had an eightfold increased odds of 'serious diff

139 (low dose) can be used in patients for whom vertigo has not been controlled by medical measures.

140 unction or with benign paroxysmal positional vertigo have been published recently, adding to the smal

141 ugh many patients with positionally provoked vertigo have typical benign paroxysmal positional vertig

142 ange of neurological symptoms from tinnitus, vertigo, headaches, and deafness to blindness and convul

143 tes type 2 and hyperlipidemia presented with vertigo, headaches, mainly during physical activity and

144 when associated with comorbidities including vertigo, hearing loss, and insomnia.

145 The identification of migrainous vertigo, however, is hampered by a lack of standardized

146 according to the literature, which included vertigo (ICD-9-CM code 386), insomnia (ICD-9-CM code 780

147 Vertigo in and around magnetic resonance imaging (MRI) m

148 into a single diagnostic algorithm for acute vertigo in the ED could enhance accuracy and streamline

149 ular condition (benign paroxysmal positional vertigo) in acute patients with clinically apparent vest

150 Other common causes of vertigo include vestibular neuritis, Meniere's syndrome,

151 he recent literature concerning cervicogenic vertigo including vertigo associated with rotational ver

152 iness Handicap Inventory, Neuropsychological Vertigo Inventory, Meniere Disease Patient-Oriented Symp

153 Benign paroxysmal positional vertigo is a common disorder of the inner ear that shoul

154 Vertigo is a subtype of dizziness, which results from an

155 Vertigo is often the most debilitating symptom associate

156 Although benign paroxysmal positional vertigo is usually a self-limited disorder, treatment wi

157 Visually-induced dizziness (visual vertigo) is a core symptom of Persistent Perceptual Post

158 high-frequency sensorineural hearing loss or vertigo, is not uncommon.

159 is characterised by intermittent episodes of vertigo lasting from minutes to hours, with fluctuating

160 verview on episodic ataxia, benign recurrent vertigo (mainly migraine-associated vertigo), bilateral

161 versely benign conditions such as migrainous vertigo may have clinical characteristics of central dis

162 For example, migrainous vertigo may have oculomotor abnormalities suggestive of

163 vidence highlights the difficulty that acute vertigo may sometimes pose to the clinician.

164 ation, the 3 most common causes of recurrent vertigo-MD, VM, and BPPV-had considerable medical costs

165 onic syndromes, benign paroxysmal positional vertigo, Meniere disease, vestibular migraine and persis

166 igher were neutropenia (n = 2) and dizziness/vertigo (n = 1).

167 The other 54 cases were isolated vertigo (n=23), non-NINDS binocular visual disturbance (

168 differences were found, the major ones being vertigo, neck pain and other pain syndromes, as well as

169 On a 1-hour dosing schedule, ataxia, vertigo, nystagmus, and a motor aphasia were the princip

170 n debilitating symptoms, such as spontaneous vertigo, nystagmus, and oscillopsia.

171 Hearing loss and vertigo occur when there is an imbalance between the two

172 He has a 4-year history of episodic vertigo of several hours' duration and fluctuating, prog

173 Persistent vertigo or brainstem and cerebellar episodes can herald

174 imary outcome was change in 10- or 100-point vertigo or dizziness visual analog scale (VAS) scores at

175 ination with variable other symptoms such as vertigo or migraine.

176 8.01), nausea (OR, 3.16; 95% CI, 2.01-4.96), vertigo (OR, 6.40; 95% CI, 1.20-34.19), and nervousness

177 EDs in Nueces County, Texas, with dizziness, vertigo, or imbalance were identified, excluding those w

178 e very similar, with patients complaining of vertigo, oscillopsia, and sometimes hearing loss.

179 jection of gentamicin can be beneficial when vertigo persists despite optimal medical management.

180 hromosome 22q12 region to a broader migraine/vertigo phenotype by defining affectation status as eith

181 go have typical benign paroxysmal positional vertigo, physicians should be aware of nonbenign variant

182 , makes magnetic-field-induced nystagmus and vertigo possible.

183 Classification of dizziness by subtype (vertigo, presyncope, disequilibrium, and other) assists

184 x (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnorma

185 nar focuses on three common presentations of vertigo: prolonged spontaneous vertigo, recurrent attack

186 for identifying serious conditions in acute vertigo, recent evidence suggests that early steroid tre

187 sentations of vertigo: prolonged spontaneous vertigo, recurrent attacks of vertigo, and positional ve

188 t single-dose antihistamines provide greater vertigo relief at 2 hours than single-dose benzodiazepin

189 that although meclizine may offer immediate vertigo relief, use is incongruent with guideline-concor

190 t establishes that a neck disturbance causes vertigo remains the critical problem that must be solved

191 r tinnitus, non-conductive hearing loss, and vertigo, respectively, were 1.332 (95% CI = 1.147-1.547)

192 Symptoms of hearing loss, vertigo, rhinitis or rhinosinusitis, epistaxis, obstruct

193 ssment, we also frequently observe a loss of vertigo sensation in patients with acute TBI, common inn

194 tem and cerebellar dysfunction or persistent vertigo several months before developing CA.

195 67.6%%]), group C had greater improvement in vertigo severity than group A (mean [SD] VAS score, -5.6

196 The primary outcome was change in vertigo severity using a 10-point visual analog scale (V

197 s (Lorentz forces) predicts that the induced vertigo should depend on the orientation of the magnetic

198 D and its four predecessors (phobic postural vertigo, space-motion discomfort, chronic subjective diz

199 erapy used in Eastern countries, may relieve vertigo symptoms without lethargy.

200 Decreases in visual vertigo symptoms, anxiety and depression correlated with

201 and symptoms (headache, numbness, weakness, vertigo, syncope, diplopia, hypotension, floaters, other

202 Although the commonest vertigo syndromes are benign, serious conditions such as

203 erstanding the more common familial episodic vertigo syndromes, particularly those associated with mi

204 f tinnitus, non-conductive hearing loss, and vertigo than comparison patients.

205 Benign positional vertigo, the most common cause of vertigo, can now be cu

206 ase studies for asthma, type 2 diabetes, and vertigo, the optimal PRS model generated with PNL using

207 ent in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AM

208 rineural hearing loss, often associated with vertigo, tinnitus, and aural fullness, and believed to b

209 a diagnosis of benign paroxysmal positional vertigo, triggered undifferentiated dizziness, spontaneo

210 uld focus on the determination of peripheral vertigo types that can benefit from sodium bicarbonate a

211 s or a history of hearing loss, tinnitus, or vertigo underwent additional radiologic and audiologic e

212 For vertigo, unlike the other diseases, individual method an

213 ent loss of consciousness, effort-associated vertigo, upper limb weakness and temporary vision proble

214 e classified the brainstem symptoms isolated vertigo, vertigo with non-focal symptoms, isolated doubl

215 Vertigo was most discomforting when head pitch was aroun

216 Hearing loss and vertigo were evaluated at baseline and at completion of

217 lunteers, prophylactic treatment, or induced vertigo were excluded, as were studies that compared 2 m

218 imaging, cochlear prostheses and aspects of vertigo which reflect the considerable advances that hav

219 Isolated vertigo with horizontal positional nystagmus as an impen

220 These clinical findings suggest that vertigo with horizontal positional nystagmus, even in th

221 tudy has demonstrated effective treatment of vertigo with migraine therapy.

222 sented to hospital because of sudden, severe vertigo with nausea, impaired balance and disturbed visi

223 ied the brainstem symptoms isolated vertigo, vertigo with non-focal symptoms, isolated double vision,

224 on-NINDS binocular visual disturbance (n=9), vertigo with other non-focal symptoms (n=10), isolated s

225 recent advances in the genetics of recurrent vertigo, with an overview on episodic ataxia, benign rec

226 g constellation of perinfusional aphasia and vertigo, with either ataxia of over 2 weeks' duration or

227 Adults with peripheral vertigo within 24 hours of onset were enrolled.

228 ebellum and lateral medulla can present with vertigo without other localizing symptoms.